Hull A R
Semin Nephrol. 1997 May;17(3):160-9.
Although hemodialysis began in the early 1960s, it did not begin to really grow until 1973, when the Federal government started to pay for end-stage renal disease (ESRD) treatment under Medicare. Since then, the Health Care Financing Administration (HCFA) has made a series of mistakes while maintaining this very successful program. This article traces the steps HCFA took, and the responses by the providers that produced the situation we have today. This program pays the lowest amount for hemodialysis of any industrialized nation, and most likely as a result has the highest mortality rate (23%) of any of the same countries. The problem as outlined is that HCFA attempted to ration by price while ignoring quality. This has been compounded by the providers finding more and more ways to reduce cost to continue to make a profit while not improving quality. The result is a program that could have been much better, and a patient population that has suffered.
尽管血液透析始于20世纪60年代初,但直到1973年才真正开始发展,当时联邦政府开始根据医疗保险为终末期肾病(ESRD)治疗提供资金。从那时起,医疗保健财务管理局(HCFA)在维持这个非常成功的项目时犯了一系列错误。本文追溯了HCFA采取的步骤,以及供应商的反应,正是这些导致了我们如今面临的局面。在所有工业化国家中,该项目支付的血液透析费用是最低的,而且很可能正因如此,在这些国家中它的死亡率也是最高的(23%)。所概述的问题是,HCFA试图通过价格来进行配给,却忽视了质量。供应商们找到了越来越多降低成本的方法,以便在不提高质量的情况下继续盈利,这使问题变得更加复杂。结果就是一个本可以好得多的项目,以及一群深受其害的患者。